Glioblastomas are highly malignant tumors of the central nervous system that are resistant to radiation and chemotherapy [1] . We explored the role of the phosphatidylinositol (PI) 3-kinase signal transduction pathway in glioblastomas, as this pathway has been shown to inhibit apoptosis induced by cytokine withdrawal and the detachment of cells from the extracellular matrix [2] . Components of this pathway have been implicated in tumor development [3] [4] [5] [6] . We show that glioblastoma cells, in contrast to primary human astrocytes, contain high endogenous protein kinase B (PKB/Akt) activity and high levels of PI 3,4,5-triphosphate (PI(3,4,5)P 3 ) and PI(3,4)P 2 , the lipid products of PI 3-kinase. These glioblastoma cells express mutant forms of the putative 3¢ phospholipid phosphatase PTEN, also known as MMAC. Expression of wild-type PTEN derived from primary astrocytes, but not of mutant forms of PTEN, reduced the levels of 3¢ phosphoinositides and inhibited PKB/Akt activity. PTEN antagonized the activation of PKB/Akt by growth factors, by activated PI 3-kinase and by PI-dependent protein kinase-1 (PDK1), but did not antagonize the phospholipid-independent activation of PKB/Akt lacking the pleckstrin homology (PH) domain. These results suggest a role for PTEN in regulating the activity of the PI 3-kinase pathway in malignant human cells. 
We have shown previously that a number of glioblastoma multiform (GM) cell lines are resistant to apoptosis induced by ionizing radiation. One cell line, SF188, was shown to undergo extensive radiation-induced apoptosis, however [7] . These observations prompted us to examine whether the activity of the PI 3-kinase pathway was differentially regulated between these cell lines.
The activity of endogenous PKB/Akt in U87 MG cells, a cell line that is markedly resistant to radiation-induced apoptosis, is elevated relative to SF188 cells growing in either serum-starved conditions or in the presence of 10% serum ( Figure 1a ). In addition, phosphorylation of PKB/Akt on Ser473, a residue implicated in the activation of the kinase [8] , is also increased in U87 MG cells compared with SF188 cells (Figure 1a ). The dramatic difference in PKB/Akt activity between these two cell lines led us to extend this analysis to more GM cell lines. With the exception of the SF188 cells, all of the seven GM cell lines examined had elevated PKB/Akt activity relative to human astrocytes, the normal cells from which glioblastomas are derived. In each case, PKB/Akt activity was abolished by pretreatment of the cells with the PI 3-kinase inhibitor LY294002 [9] (Figure 1b) . Our data show that in most GM tumor cells the PI 3-kinase-PKB signal transduction pathway is dysregulated. To determine the level of dysregulation, we examined the levels of 3′ phosphorylated inositol phospholipids, the products of PI 3-kinase activity. The levels of PI(3,4)P 2 and PI(3,4,5)P 3 were increased in U87 MG cells compared with either SF188 cells or primary astrocytes (Figure 1c) , indicating that the putative genetic abnormality lies upstream of, or at the level of, PI 3-kinase. Addition of LY294002 to U87 MG cells reduced the levels of these phospholipids ( Figure 1c ).
We sought to identify the genetic mutation leading to dysregulation of the PI 3-kinase-PKB pathway and investigated whether mutations in the PTEN gene were responsible. This tumor suppressor gene encodes a phosphatase and is located on chromosome 10q23. It has previously been shown to be mutated or deleted in several human malignancies, including a large number of glioblastoma tumors [10] . Recent studies show that PTEN can dephosphorylate the 3′ phosphate of PI(3,4,5)P 3 in vitro [11] . We therefore examined whether PTEN mutations could explain the increased levels of 3′ phospholipids and the increased PKB/Akt activity in GM cell lines. Several of the cell lines shown in Figure 1 have previously been shown to contain mutations or deletions in PTEN (U87 MG, U373 [12] , U138 [13] and U251 [14] ), which we confirmed. In addition, sequencing PTEN from the remaining cell lines, SF188, SF126 and SF210, revealed two point mutations in SF210 (I101T and K164R) and one point mutation (G129R) in SF126. This latter mutation occurs in the conserved phosphatase domain, has been found in tumor specimens, and has been shown to abolish the intrinsic phosphatase activity of PTEN in vitro [15] . We found that the SF188 line -which had low levels of 3′ phospholipids and low PKB/Akt activity -expresses wild-type PTEN. This is consistent with the hypothesis that PTEN regulates PKB/Akt activity. Wild-type PTEN derived from primary astrocytes expressed transiently in U87 MG cells (Figure 2a ) or stably in U87 MG cells and U251 cells (Figure 2b ) dramatically reduced PKB/Akt activity and phosphorylation. In contrast, expression of the mutant PTEN alleles derived from the GM cell lines SF126 ( Figure 2a ) and U138, U251 and U373 (data not shown) were unable to reduce PKB/Akt activity in U87 MG cells. PTEN derived from the SF210 line was still able to reduce PKB/Akt activity, although to a lesser extent than wild-type PTEN. Stable expression of wild-type PTEN also reduced PKB/Akt activity in three other GM cell lines expressing endogenous mutant PTEN, but had no effect on the PKB/Akt activity in SF188 cells (data not shown). These results indicate that the high PKB/Akt activity in GM cell lines is a direct consequence of inactivating PTEN mutations in these cells. Stable expression of wild-type PTEN in U87 MG and U251 cells also reduced the levels of the phospholipids PI(3,4)P 2 and PI(3,4,5)P 3 (data not shown), confirming that the target of PTEN is upstream of, or at the level of, PI 3-kinase. The expression of wild-type PTEN inhibited the proliferation of U87 MG cells, consistent with previous reports [14, 16] .
To further investigate the mechanism by which PTEN reduces PKB/Akt activity, we examined the ability of PTEN to antagonize the activation of PKB/Akt by different stimuli. PTEN inhibited activation of PKB/Akt by platelet-derived growth factor (PDGF), by an activated version of PI 3-kinase (PI3K-CAAX), and by PDK1 in both COS1 cells and NIH3T3 cells (Figure 3a,b) . All these agents require 3′ phospholipids for their ability to activate PKB/Akt, as they are all inhibited by LY294002 (data not shown). The activation of a form of PKB lacking its PH domain (∆PH-PKB) by PDK1 lacking its PH domain (∆PH-PDK), which is less dependent on 3′ phospholipids, was not affected by the expression of PTEN, however (Figure 3c) . Similarly, the activity and phosphorylation of ∆PH-PKB transiently expressed in U87 MG cells was more resistant to inactivation by PTEN than full-length PKB/Akt (Figure 3d ). The resistance of ∆PH-PKB to inactivation by PTEN is probably because ∆PH-PKB is activated by PDK1 in a phospholipid-independent manner [17, 18] , further reinforcing the role of PTEN in controlling the PI 3-kinase-PKB pathway through the regulation of phospholipid levels.
The involvement of the PI 3-kinase pathway in inhibiting apoptosis and promoting proliferation [19] suggests that this signal transduction pathway has an important role in human tumorigenesis. To date, however, dysregulation of this pathway has been demonstrated in only a small subset of human tumors through amplification of either PKBβ/Akt2 [5, 6] [10] , our data implicate dysregulation of the PI 3-kinase pathway as a key mediator of human carcinogenesis.
Supplementary material
Additional methodological detail is published with this paper on the internet. (d) U87 MG cells were transfected with either full-length HA-PKB (PKB) or ∆PH-PKB, together with either empty vector, wild-type PTEN from primary astrocytes (WT) or PTEN from SF126 cells (G129R). Exogenous PKB/Akt was immunoprecipitated, and the immune complex assayed for kinase activity (PKB activity), and immunoblotted using antibodies against PKB/Akt phosphorylated on either Ser473 (P-PKB S473) or Thr308 (P-PKB T308) or using the C-12 anti-PKBα antibody (PKB). A portion of the lysate was also probed with a PTEN antibody.
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Materials and methods

Cell culture and transfections
Cells were acquired and maintained as described [S1]. COS1 cells and NIH3T3 cells were transfected using Lipofectamine Plus (Gibco) and U87 MG cells were transfected with FuGene6 (Boehringer) following the manufacturers' instructions. For retroviral infections, 80% confluent cells were infected with retrovirus expressing PTEN subcloned into pLXSN and infected pools were selected and maintained in 500 µg/ml G418.
